| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
|
Lancet
|
2008
|
3.00
|
|
2
|
Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis.
|
Nat Genet
|
2013
|
2.60
|
|
3
|
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.
|
Arthritis Rheum
|
2008
|
2.56
|
|
4
|
Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies.
|
Arthritis Rheum
|
2004
|
2.31
|
|
5
|
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis.
|
Arthritis Care Res (Hoboken)
|
2012
|
2.21
|
|
6
|
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma.
|
Arthritis Care Res (Hoboken)
|
2012
|
1.84
|
|
7
|
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.
|
Arthritis Rheumatol
|
2014
|
1.51
|
|
8
|
Very high serum ferritin levels are associated with increased mortality and critical care in pediatric patients.
|
Pediatr Crit Care Med
|
2011
|
1.51
|
|
9
|
Developing standards of care for patients with juvenile idiopathic arthritis.
|
Rheumatology (Oxford)
|
2010
|
1.51
|
|
10
|
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.
|
Arthritis Rheum
|
2003
|
1.42
|
|
11
|
Old challenges and new directions in pediatric rheumatology.
|
J Rheumatol
|
2006
|
1.40
|
|
12
|
An i2b2-based, generalizable, open source, self-scaling chronic disease registry.
|
J Am Med Inform Assoc
|
2012
|
1.39
|
|
13
|
Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus.
|
Arthritis Care Res (Hoboken)
|
2012
|
1.33
|
|
14
|
Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference.
|
Arthritis Care Res (Hoboken)
|
2010
|
1.32
|
|
15
|
Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis.
|
Arthritis Res Ther
|
2009
|
1.26
|
|
16
|
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
|
Arthritis Rheum
|
2006
|
1.16
|
|
17
|
Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.
|
Arthritis Rheum
|
2013
|
1.13
|
|
18
|
Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations.
|
Rheumatology (Oxford)
|
2009
|
1.10
|
|
19
|
Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis.
|
Arthritis Rheum
|
2008
|
1.09
|
|
20
|
Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry.
|
Arthritis Care Res (Hoboken)
|
2010
|
1.06
|
|
21
|
Polysomnography and self-reported sleep, pain, fatigue, and anxiety in children with active and inactive juvenile rheumatoid arthritis.
|
J Pediatr Psychol
|
2007
|
1.06
|
|
22
|
Summary of worldwide pediatric malignancies reported after exposure to etanercept.
|
Pediatr Rheumatol Online J
|
2010
|
1.03
|
|
23
|
Sleep disturbance, daytime sleepiness, and neurocognitive performance in children with juvenile idiopathic arthritis.
|
Sleep
|
2010
|
1.01
|
|
24
|
Health-related quality of life, physical function, fatigue, and disease activity in children with established polyarticular juvenile idiopathic arthritis.
|
J Rheumatol
|
2009
|
1.00
|
|
25
|
Gene expression profiling in neutrophils from children with polyarticular juvenile idiopathic arthritis.
|
Arthritis Rheum
|
2009
|
1.00
|
|
26
|
Hierarchy of risk of childhood-onset rheumatoid arthritis conferred by HLA-DRB1 alleles encoding the shared epitope.
|
Arthritis Rheum
|
2012
|
0.98
|
|
27
|
Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS).
|
Ann Rheum Dis
|
2012
|
0.97
|
|
28
|
Intraarticular corticosteroid injections of the temporomandibular joint in juvenile idiopathic arthritis.
|
J Rheumatol
|
2008
|
0.95
|
|
29
|
Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.95
|
|
30
|
Susceptibility to childhood-onset rheumatoid arthritis: investigation of a weighted genetic risk score that integrates cumulative effects of variants at five genetic loci.
|
Arthritis Rheum
|
2013
|
0.93
|
|
31
|
Measuring clinical response and remission in juvenile idiopathic arthritis.
|
Curr Opin Rheumatol
|
2007
|
0.92
|
|
32
|
Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease.
|
Arthritis Care Res (Hoboken)
|
2010
|
0.90
|
|
33
|
Development and retrospective validation of the juvenile spondyloarthritis disease activity index.
|
Arthritis Care Res (Hoboken)
|
2014
|
0.88
|
|
34
|
Whole blood gene expression profiling predicts therapeutic response at six months in patients with polyarticular juvenile idiopathic arthritis.
|
Arthritis Rheumatol
|
2014
|
0.87
|
|
35
|
Remission in juvenile idiopathic arthritis: current facts.
|
Curr Rheumatol Rep
|
2010
|
0.86
|
|
36
|
Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale.
|
Arthritis Rheum
|
2004
|
0.86
|
|
37
|
Heterotopic ossification of the temporomandibular joint in juvenile idiopathic arthritis.
|
J Rheumatol
|
2011
|
0.85
|
|
38
|
Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis.
|
Arthritis Rheum
|
2010
|
0.85
|
|
39
|
Disease activity and fatigue in juvenile idiopathic arthritis.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.85
|
|
40
|
Evolution of paediatric-specific vasculitis classification criteria.
|
Ann Rheum Dis
|
2010
|
0.83
|
|
41
|
Using registries to identify adverse events in rheumatic diseases.
|
Pediatrics
|
2013
|
0.83
|
|
42
|
Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.
|
Paediatr Drugs
|
2010
|
0.82
|
|
43
|
Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology.
|
Pediatr Rheumatol Online J
|
2012
|
0.82
|
|
44
|
Sleep disturbances and neurobehavioral functioning in children with and without juvenile idiopathic arthritis.
|
Arthritis Care Res (Hoboken)
|
2011
|
0.81
|
|
45
|
Juvenile idiopathic arthritis in relation to maternal prenatal smoking.
|
Arthritis Care Res (Hoboken)
|
2015
|
0.80
|
|
46
|
Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus.
|
Arthritis Rheumatol
|
2015
|
0.79
|
|
47
|
Characterisation of gamma delta (γδ) T cell populations in patients with sepsis.
|
Cell Biol Int
|
2014
|
0.77
|
|
48
|
Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project.
|
Arthritis Care Res (Hoboken)
|
2015
|
0.77
|
|
49
|
Injectable tumor necrosis factor α inhibitors and outpatient antimicrobial use in children with rheumatic diseases: analyses of prescription claims from a pharmacy benefit manager database.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.77
|
|
50
|
Perinatal exposures and Kawasaki disease in Washington State: a population-based, case-control study.
|
Pediatr Infect Dis J
|
2012
|
0.77
|
|
51
|
HACCP-based food safety management systems: great in theory but can we really make them work in practice?
|
Perspect Public Health
|
2014
|
0.75
|
|
52
|
Methotrexate and injectable tumor necrosis factor-α inhibitor adherence and persistence in children with rheumatic diseases.
|
J Rheumatol
|
2012
|
0.75
|
|
53
|
Developing women leaders in medicine at the grass roots level: evolution from skills training to institutional change.
|
J Pediatr
|
2007
|
0.75
|
|
54
|
The food safety impact of salt and sodium reduction initiatives.
|
Perspect Public Health
|
2014
|
0.75
|